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Genotoxicity: damage to DNA and its consequences 
 
David H. Phillips and Volker M. Arlt  
  
Institute of Cancer Research, Section of Molecular Carcinogenesis, Brookes Lawley Building, 
Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom 
 
Abstract 
 A genotoxin is a chemical or agent that can cause DNA or chromosomal damage. Such 
damage in a germ cell has the potential to cause a heritable altered trait (germline mutation). DNA 
damage in a somatic cell may result in a somatic mutation, which may lead to malignant 
transformation (cancer). Many in-vitro and in-vivo tests for genotoxicity have been developed that, 
with a range of endpoints, detect DNA damage or its biological consequences in prokaryotic (e.g. 
bacterial) or eukaryotic (e.g. mammalian, avian or yeast) cells. These assays are used to evaluate the 
safety of environmental chemicals and consumer products and to explore the mechanism of action 
of known or suspected carcinogens. Many chemical carcinogens/mutagens undergo metabolic 
activation to reactive species that bind covalently to DNA and the DNA adducts thus formed can be 
detected in cells and in human tissues by a variety of sensitive techniques. The detection and 
characterisation of DNA adducts in human tissues provides clues to the aetiology of human cancer. 
Characterisation of gene mutations in human tumours, in common with the known mutagenic 
profiles of genotoxins in experimental systems, may provide further insight into the role of 
environmental mutagens in human cancer. 
Keywords: Carcinogenicity, mutagenicity, mutation, DNA adduct, micronucleus, chromosomal 
aberration, transgenic animals, DNA strand break, Ames test, comet assay, 32P-postlabelling, 
immunoassay, mass spectrometry, human biomonitoring. 
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Introduction 
Cancer is a genetic disease arising from a series of somatic mutations. Mutations in DNA 
may arise spontaneously, or as a result of chemical action by agents of either endogenous or 
exogenous origin. Genetic toxicology is the study of agents that can damage the DNA and 
chromosomes of cells. In eukaryotic organisms, genetic damage in somatic cells may lead to 
malignancy. In germ cells it may adversely affect reproduction or provoke heritable mutations. 
Consequently, investigating the genotoxicity of a compound is often carried out in the context of 
seeking to understand its mechanism of carcinogenicity and this has become an essential component 
of the process of risk assessment for human exposure to a known animal carcinogen. Investigating 
genotoxicity is also important in assessing whether or not a new compound is a carcinogen and/or 
mutagen, and this process contributes to the more fundamental process of hazard identification. 
Understanding mechanisms of carcinogenesis often relies on analysis of the molecular and 
cellular effects of carcinogens in laboratory experiments. This is a necessary simplification of a 
complex process and while such approaches often provide critical evidence for mechanisms, it must 
be recognised that laboratory models rarely cover all the possible facets of the process, and there are 
many instances in which the classification of a carcinogen is not a straightforward matter. 
A genotoxic carcinogen typically induces tumours in multiple organs of rodents, may be 
carcinogenic to more than one species and to both males and females. In addition, there is often 
evidence of a dose-response relationship for tumour induction, of the type that does not suggest 
evidence of a threshold. In contrast, non-genotoxic carcinogens are more likely to be characterised 
by tumour induction in a single species and/or in a single tissue and, commonly, in one sex only, 
often at low incidence and only at high dose with associated evidence of toxicity. Multi-species, 
multi-organ carcinogens are more likely to be human carcinogens and, indeed, most agents 
classified as human carcinogens by the International Agency for Research on Cancer (IARC) are 
genotoxic. It is thus a general principle that chemicals that are carcinogenic in animals by a 
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genotoxic mechanism pose a greater potential risk to humans than non-genotoxic carcinogens, and 
the default assessment of genotoxins is that human exposure at any level poses a risk. For such 
agents exposure should be As Low As Reasonably Achievable (ALARA). For non-genotoxic 
carcinogens it may be possible to define a threshold, i.e. a level of exposure below which the agent 
does not present a carcinogenic risk to humans.  
In some animal models carcinogenicity can be divided into an initiation phase, involving a 
single treatment with a genotoxic agent, followed by promotion, involving repeated treatments with 
a non-genotoxic agent. A common feature is that initiation is considered irreversible, such that the 
promotion phase can be delayed significantly yet still ultimately result in tumour formation. 
Furthermore the tumour response may be absent or greatly reduced if the initiator is applied after 
the promoter, or if treatment is with either initiator or promoter alone. Although this model of 
initiation and promotion has served well as an experimental system for defining genotoxicity and 
for some studies of mechanisms of tumour formation, it appears to present an over-simplification of 
the process, particularly when considering the mechanism(s) of carcinogenesis in humans. 
Epidemiological evidence on the age distribution of many common cancers suggested that cancer 
induction is a multi-stage process, involving as many as 5-7 distinct events [1]. Although this 
conclusion was reached more than 50 years ago, before anything was known about the changes 
associated with malignancy were identified or understood, genetic analysis of tumours over the last 
10 or more years has borne out this out. Current understanding is that the accumulation of a number 
of mutations (5-7 is a reasonable estimate) in critical genes in progenitor cells leads to the 
manifestation of the malignant phenotype. 
Phenotypically, malignancy is characterised by six essential alterations in cell physiology: 
(i) self-sufficiency in growth signals, (ii) insensitivity to growth-inhibitory signals, (iii) evasion of 
programmed cell death (apoptosis), (iv) limitless replicative potential, (v) angiogenesis and (vi) 
tissue invasion and metastasis [2]. Although there is not yet an exact match between the genotypic 
 4
and phenotypic characteristics of tumours, it is logical to conclude that carcinogenesis is driven by 
the accumulation of critical mutations in cells that converts them and their progeny from normal 
cells to fully malignant ones. The identification of mutations in specific genes in human cancers has 
demonstrated that they are associated with both early and late stages of tumour progression [3]. 
Thus, while it is thought that DNA damage (often involving binding to DNA by carcinogens) 
occurs in the early, initiating stages of carcinogenesis, it is probable that genotoxic events are also a 
feature of later stages of the multistage process, now that it is apparent that gene mutation is 
associated with several stages of carcinogenesis. 
 
Short-term tests for genotoxicity 
In the context of short-term tests for mutagenicity and genotoxicity, a genotoxic agent is one 
that induces point mutations, deletions, insertions, gene amplifications, chromosomal 
rearrangements or numerical chromosomal changes (aneuploidy). The tests are therefore designed 
to detect one or more type of genetic alteration. Since such biological properties result directly or 
indirectly from DNA damage, other assays have been developed to identify this damage directly. 
No single assay, no matter how extensive the protocol, can detect all genotoxic chemicals [4]. 
Therefore, it is generally accepted that a number of tests must be conducted to evaluate whether a 
chemical is genotoxic or not, and often a weight-of-evidence approach must be taken to evaluate the 
results. 
A number of organisations and advisory bodies have produced guidelines in the last ten 
years. These include the International Programme on Chemical Safety (IPCS), the International 
Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH), and the International Workshop on Genotoxicity Testing (IWGT). These and 
other guidelines have been reviewed and compared by Cimino [5]. 
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For a test to be useful it should be both sensitive and specific (see Table 1). Several 
guidelines recommend that a test battery for genotoxicity should include: 1) a test for gene mutation 
in bacteria; 2) an in-vitro test that includes cytogenetic evaluation of chromosomal damage in 
mammalian cells or an in-vitro mammalian cell mutagenicity test such as the mouse lymphoma Tk 
assay; 3) an in-vivo test for chromosomal damage using rodent haematopoietic cells. Some 
guidelines advise that negative results in both of the first two assays may in some cases (e.g. a low-
volume chemical where the potential for human exposure is minimal) remove the necessity of 
conducting the third, in-vivo, test. More recently, however, the Seventh Amendment to the 
European Union Cosmetics Directive that will ban the marketing of cosmetics and personal care 
products containing ingredients tested in animals has highlighted the need for better in-vitro tests 
for toxicity and genotoxicity [6]. 
 
Bacterial mutagenicity testing 
 The most widely used bacterial assay to detect chemically-induced gene mutations is the 
Ames Salmonella assay developed by Bruce Ames [7; 8]. Salmonella typhimurium strains that 
contain defined mutations in the histidine locus form the basis of this ‘reverse’ mutation assay. In 
the assay, bacteria are incubated with a range of concentrations of the test compound to induce a 
second mutation that directly reverses or suppresses the original mutations and, thus, restores the 
biological function to the non-functional histidine gene. Strains of S. typhimurium used in the Ames 
assay are auxotrophic for histidine and revertants are selected by their ability to grow in the absence 
of this amino acid. Two of the most commonly used S. typhimurium strains are TA98 and TA100. S. 
typhimurium TA98 has a hisD3052 mutation detecting frame-shift reversion events whereas S. 
typhimurium TA100 has a hisG46 mutation detecting base-pair substitution events [9]. The great 
strength of the assay is the ability to identify and score a small number of mutants from a relative 
large population of unmutated cells. However, as bacteria lack many endogenous metabolic 
 6
pathways that are required for the bioactivation of the test chemicals, extracts of mammalian liver 
(usually rat) are incorporated as an exogenous activation system [9]. Fractionated tissue 
homogenate such as the 9000 g supernatant (S9 fraction), prepared from the livers of rats pretreated 
with Aroclor 1254, provides a rich source of mixed-function mono-oxygenases required for 
bioactivation. 
 The Ames assay can either be used to assess the mutagenic potency of a chemical as part of 
the toxicological screening, or else it can form part of a detailed mechanistic examination of the 
chemical’s mutagenic potential. In the current ICH and OECD Guidelines, the use of 5 tester strains 
is recommended: TA98, TA100 and TA1535; TA1537 or TA97 or TA97a; TA100 (or alternatively 
one of several Escherichia coli WP2 strains). In order to make the assay more sensitive, these 
strains contain an rfa mutation resulting in defective lipopolysaccharide and increased permeability 
to large test molecules, or a deletion in the uvrB gene making the strains deficient in nucleotide 
excision repair. Some strains (e.g. S. typhimurium TA98 and TA100) include additionally a plasmid 
(pKM101) containing umuDC genes encoding for a translesion-synthesis DNA polymerase that 
elicits error-prone repair [10]. Using genetically-engineered S. typhimurium strains that either 
overexpress or lack enzymes required for the bioactivation of different carcinogens can provide 
useful information on their metabolism [11; 12]. Moreover, ‘humanised’ S. typhimurium strains 
with defined human enzymes have been developed in order to identify which human enzymes are 
involved in bioactivation and to improve the relevance of Ames Salmonella assay for detecting 
agents hazardous to humans [13]. 
 
Mammalian mutagenicity testing 
 The mouse lymphoma assay (MLA) is the most widely used mammalian gene mutation 
assay [14]. It detects various mutation events involving the thymidine kinase (Tk) gene in 
L5178Y/Tk+/− 3.6.2C mouse lymphoma cells [15; 16]. The gene coding for thymidine kinase is on 
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mouse chromosome 11 and allows the cell to salvage nucleotides from the culture medium for reuse 
in metabolism but is not essential for cell survival. Since eukaryotic cells are diploid, heterozygous 
cells are used where two copies of the Tk gene are present but one copy has been inactivated. 
Otherwise, many mutations arising in mammalian cells cannot be selected directly, since the second 
copy of the gene would complement the first. Mutants in the MLA are detected by plating cells into 
medium containing trifluorothymidine (TFT), a thymidine analogue [17]. Thus, toxic TFT placed in 
the medium will be transported into normal Tk+/− (non-mutated) cells that consequently die, while 
Tk−/− mutants will be resistant to the toxic TFT and survive, and subsequently form clones that can 
be counted. The L5178Y system is the recommended in-vitro mammalian cell mutation assay 
because it detects a wide range of genetic alterations, including both mutations and chromosomal 
damage [18]. 
   
Transgenic rodent mutation assays 
 Transgenic rodent mutation assays were first developed in the 1990s [19; 20], MutaMouse 
and Big Blue Mouse and Rat being the assays most widely used [21; 22]. MutaMouse carry a 
recombinant λ-bacteriophage vector containing the entire Escherichia coli lacZ (β-galactosidase) 
[21]. Mutations occurring in the lacZ gene are measured by positive selection of lacZ− mutants on 
phenylgalactosidase (P-gal)-containing medium using an indicator bacteria strain (E. coli lacZ− 
galE−). In the presence of P-gal only lacZ− bacteria (mutants) will grow and produce plaques, 
whereas lacZ+ (i.e. non-mutants) produce the enzyme β-galactosidase converting P-gal into 
galactose and subsequently into the toxic intermediate uridine diphosphate (EDP)-galactose, which 
accumulates in E. coli galE− and kills the cells. In the Big Blue system, the reporter gene is lacI 
contained in a λ-bacteriophage vector [22]. Mutants occurring in the lacI gene are selected on 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal)-containing medium using an E. coli lacI− 
indicator strain. Wild-type lacI (non-mutants) will repress the lac operon encoding for β-
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galactosidase forming clear plaques whereas lacI− mutants will produce β-galactosidase that uses 
X-gal as substrate producing blue coloured plaques that can be counted. Since the ‘reporter’ genes 
that serve as targets for detecting mutations are incorporated into the chromosomes of the transgenic 
mice or rats, somatic mutations can be measured within any tissue of the exposed animal, and more 
importantly enables mutation induction and measurement in the actual target tissue for tumour 
development. General guidance on recommended protocols has been published [23; 24]. 
 The lacI/lacZ models are well suited to detect point mutations but unsuited for the detection 
of large deletion mutations induced by clastogens [19]. However, the coding size of, for instance, 
the lacZ gene is about 3 kb (kilo base pairs), which is not compact enough to routinely identify 
mutations by DNA sequencing. Thus, a new reporter gene, the cII gene of the λ phage, has been 
used and is applicable to both MutaMouse and Big Blue Mouse systems [25]. The cII gene is 
susceptible to mutagenesis, just as is lacI or lacZ, but has the advantage over them that the coding 
region is only 300 base pairs and can easily be sequenced in a single run. An alternative transgenic 
mouse model, gpt delta, is reported to be suitable for the detection of large deletions [26]. 
 
Tests for chromosome damage 
 Structural chromosome changes that can be detected by conventional in-vitro cytogenetics 
are chromosome aberrations (CA), micronuclei (MN) and sister chromatid exchanges (SCE).  
 Structural CA are changes in normal chromosome structure or number that can occur in cells 
after chemical exposure or radiation. They result from direct DNA breakage, replication on a 
damaged DNA template, inhibition of DNA synthesis, and other mechanisms (e.g. inhibition of 
topoisomerase II) [27]. Cells commonly used to measure structural CA are human peripheral blood 
lymphocytes or established lymphoblastoid cell lines [28]. Peripheral lymphocytes are popular cells 
for in-vitro studies because they are human primary cells, have a low spontaneous rate of 
chromosomal damage, and can be easily cultured with a stable karyotype (2n=46). Structural CA 
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are generally scored in metaphase-arrested cells after Giemsa staining [29]. For over 30 years 
structural CA in human peripheral blood lymphocytes have been used in occupational and 
environmental settings as a biomarker of exposure and a marker of cancer risk [30; 31]. 
 The in-vitro micronucleus test allows the detection of both structural (clastogenic) and 
numerical (aneugenic) chromosome changes using interphase cells [32]. Thus, MN represents a 
measure of both chromosome breakage and chromosome loss, and an increased frequency of 
micronucleated cells is a biomarker of genotoxic effects. MN formed by clastogenicity induction 
can be distinguished from those produced by aneugenic activity by the absence of centrometric 
DNA or kinetochore proteins in the MN using centrometric probes or kinetochore antibodies [33]. 
The standard in-vitro micronucleus test is usually performed in lymphocytes [34], the cytokinesis-
block micronucleus assay being the most widely used method. This assay is specifically restricted 
to once-divided cells and these cells are recognised by their binucleated appearance after inhibition 
of cytokinesis by cytochalasin-B [35]. Restricting the scoring of MN to binucleate cells prevents 
confounding effects that can be a major variable in the assay. The use of MN as a measure of 
chromosomal damage has become a standard assay both in genotoxicity testing (although an OECD 
guideline protocol has yet to be adopted) and human biomonitoring studies [36; 37]. 
 The rodent micronucleus test is a widely used and extensively validated assay to assess 
chromosome damage in vivo and has been incorporated into standard rodent toxicology screening 
assays [38; 39]. For the analysis, immature erythrocytes (i.e., polychromatic erythrocytes; 
reticulocytes) in either bone marrow or peripheral blood have been found equally acceptable when 
the rodents have been exposed to the test compound by an appropriate route. A detailed description 
of the study design and experimental procedure has been published [39; 40]. 
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Comet assay 
 The comet assay (or single-cell gel electrophoresis assay) is a simple and sensitive method 
for measuring alkali labile sites and DNA strand breaks in the DNA of mammalian cells [41]. In the 
assay, a small number of cells suspended in agar are lysed under alkaline conditions, subjected to 
electrophoresis, neutralised and stained with a fluorescent DNA dye, such as propidium iodide [42; 
43]. Cells with increased DNA damage display increased migration of the chromosomal DNA from 
the nucleus resembling the shape of a ‘comet’. Using image analysis software parameters such as 
percentage of DNA in the tail (percent migrated DNA), tail length, and tail moment (fraction of 
migrated DNA multiplied by some measure of tail length) can be determined as a measure of DNA 
damage. As an in-vivo genotoxicity assay, it has the advantage that it can be applied to a single-cell 
suspension of material from any animal tissue, allowing consideration of potential target tissues and 
also taking account of possible inaccessibility to exposure of tissues (e.g. bone marrow) required for 
other in-vivo assays. 
 Under alkaline conditions, the assay detects overt strand breaks, which can include single 
and double strand breaks, as well as transient repair-induced breaks. It also detects lesions that are 
alkali-labile, which includes AP (apurinic/apyrimidinic) sites (see below). More precise information 
on the nature of the lesions detected can be obtained by the inclusion of lesion-specific 
endonucleases in the assay protocol, which convert some types of DNA damage to strand breaks 
[44]. Formamidopyrimidine-DNA-glycosylase (FPG) has been used to detect oxidised DNA 
damage, principally 8-oxo-dGuo (7, 8-dihydro-8-oxo-2’-deoxyguanosine), with high sensitivity 
[45]. More recently, it has been reported that FPG also detects some types of alkylation damage, 
and that the human homologue of FPG, hOGG1, is a more specific endonuclease for oxidation 
products [46]. Another enzyme, endonuclease III, converts oxidised pyrimidines to strand breaks 
[44]. 
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 The comet assay is used in many studies to assess DNA damage and repair and has 
widespread application in genotoxicity testing in vitro and in vivo [47]. Since virtually any cell 
population or single-cell suspension from any tissue type can be used for analysis, the assay in 
widely used in environmental biomonitoring and human population monitoring [44; 48; 49]. 
  
Correlations of mutagenicity and carcinogenicity 
Clearly a major purpose of conducting the foregoing assays is to be able to predict whether 
or not a chemical is a carcinogen without conducting a costly and time-consuming animal bioassay. 
The reliability of such tests, both in terms of the specificity and selectivity, is a matter of ongoing 
debate, subject to the continual accumulation of new data. Where a compound known to be 
carcinogenic is not detected as a mutagen or genotoxin in such assays, or where a mutagen (or 
genotoxin) has been found to be non-carcinogenic, some sort of explanation needs to be sought. A 
carcinogen may be non-mutagenic or non-genotoxic because its mechanism of action does not 
involve DNA damage (i.e. it is a non-genotoxic carcinogen that may, for example, act as a tumour 
promoter or by inhibiting DNA methylation). On the other hand it may be that mutagenic activity of 
the genotoxic carcinogen is limited to the chromosomal level, or that unusual metabolic activation 
for activity is required and that this is not achieved in the in-vitro test. The addition of external 
enzymatic activation systems (e.g. rat liver S9) may not be adequate for some compounds, 
particularly where phase II enzymes are required or where the half-life of the reactive species may 
be short or its cell permeability limited. Strategies to overcome these shortcomings include the use 
of human liver S9 [50] and the engineering of bacteria or mammalian cells to express human 
xenobiotic metabolising genes [13; 51], but these approaches are, as yet, research tools and not part 
of the regulatory armoury. 
Non-carcinogens may test positive as mutagens if the activity in the test system is due to a 
metabolic pathway not exhibited in vivo or due to the absence of a competing detoxification 
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pathway or lack of DNA repair; or it may be that mutagenicity is limited to a particular type of 
genetic damage (e.g. aneuploidy). Alternatively it may be that mutagenicity is insufficient for 
carcinogenicity, which may require accompanying cell proliferation in the target tissue; or it may 
simply be that the in-vivo rodent models used for carcinogenicity testing may not be sufficiently 
sensitive for some weak mutagens. 
As stated earlier, it is widely recognised that no single assay can detect all genotoxic 
carcinogens, hence the evolution of the standard battery of tests. But even then, there are some 
genotoxins that go undetected by all these assays [52]. 
 
DNA adducts formed by chemical carcinogens 
Genotoxic chemical carcinogens are either directly or indirectly DNA reactive. Most 
chemical carcinogens are not chemically reactive as such, but undergo metabolic activation in 
mammalian cells to reactive intermediates that react with DNA (Table 2), hence the requirement for 
inclusion of metabolising enzymes in many in-vitro genotoxicity assay systems. Carcinogen-
induced DNA damage can take several forms. It can result in breaks in the sugar-phosphate 
backbone of the molecule, either in one of the two strands of the double helix (forming single-
strand breaks), or in both (causing double-strand breaks). Covalent binding of the carcinogen results 
in the formation of a chemically altered base (or, occasionally, phosphate group) in DNA that is 
termed an adduct. Formation of adducts at some positions of the DNA bases (for example at the N7 
position of guanine) can render the base-sugar bond unstable and lead to loss of the adducted base 
(depurination or depyrimidination). The resulting modification to DNA is the formation of an AP 
site. Some carcinogens are bifunctional and can give rise to both monoadducts and crosslinks in 
DNA, the latter being either intrastrand or interstrand crosslinks. Many cancer chemotherapeutic 
agents have this property, and it is widely held that interstrand crosslinks are cytotoxic (accounting 
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for the therapeutic properties of the drugs), while the monoadducts and intrastrand crosslinks are 
potentially mutagenic and carcinogenic. 
DNA adducts can also originate from endogenous processes, including normal metabolism, 
oxidative stress and chronic inflammation [53]. The most abundant oxidation lesion in DNA is 8-
oxo-dGuo, which can be formed by free radical attack on DNA or through normal aerobic 
metabolism. It is suspected that some genotoxic carcinogens that do not appear to directly modify 
DNA instead damage it through inducing oxidative stress leading to increased oxidative damage to 
DNA. 
In experimental studies where multiple doses of carcinogens have been administered to 
animals and both tumour outcome and DNA adduct levels have been determined, there has in 
general been found to be a linear relationship between dose and both these parameters at low dose, 
although deviations from linearity may be observed at higher doses [54]. Nevertheless the low-dose 
effects are more relevant to human exposure scenarios than the high-dose effects, which may be 
explained in part by the influence of toxicity. 
 
Methods for adduct detection 
A number of sensitive methods have been developed for the detection and characterisation 
of DNA adducts (Table 3) [54; 55]. For an assay to be applicable to human exposure, it must (i) be 
sensitive enough to detect low levels of adducts; (ii) require only microgram quantities of DNA; 
(iii) provide results quantitatively related to the exposure; (iv) be applicable to unknown adducts 
that may be formed from complex mixtures; and (v) be able to resolve, quantitate and identify 
adducts.  
 Most of the early work on adducts required the use of radiolabelled compounds (labelled 
either with 3H or 14C) at a position of the molecule where the isotope is not lost during metabolic 
activation and binding to DNA [55]. The DNA binding is then measured by the detection of 
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radioactivity in DNA isolated from exposed animals or cells in culture achieving sensitivities of 
detection of 1 adduct in 108 nucleotides with 3H-labelling, although 14C-labelling is less sensitive 
due to the lower specific activity of 14C-labelled compounds compared with 3H-labelled ones (a 
consequence of the much longer half-life of 14C compared with that of 3H) [55]. However, due to 
the highly radioactive test compounds it was not possible to use this approach in studies involving 
humans. 
 In 1981, the 32P-postlabelling technique was developed [56-58]. The method comprises a 4-
step process that involves (i) DNA digestion, (ii) a procedure that isolates or selects the adducts for 
preferential labelling, (iii) the introduction of a radiolabel into the DNA adducts using enzymatic 
[32P]phosphorylation of the nucleotide adduct and (iv) separation of the 32P-labelled adducts using 
thin layer (TLC) or high performance liquid chromatography (HPLC) [59; 60]. The assay requires 
only small (1–10 µg) quantities of DNA and is capable of detecting adducts at frequencies as low as 
1 adduct in 1010 nucleotides, making it widely applicable in human biomonitoring [61]. It can be 
used for a wide variety of classes of compounds, including polycyclic aromatic hydrocarbons 
(PAHs), aromatic and heterocyclic amines, unsaturated aldehydes, simple alkylating agents, 
reactive oxygen species, ultraviolet light (UV) radiation, and for the detection of adducts formed by 
complex mixtures [54; 62]. A limitation of the method is that it does not provide structural 
information; identification of adducts is reliant on co-chromatography using characterised synthetic 
standards [59]. A different approach using a similar experimental protocol is the chemical linkage 
of a fluorescent dye (e.g. BODIPY) to the DNA adducts, which can subsequently be separated by 
capillary electrophoresis and detected by laser-induced fluorescence (CE-LIF) [63]. Although this 
methodology is not yet sensitive enough to be applied to human samples (detection limit 1 adduct 
per 107 nucleotides) [63; 64], it has proved to be a suitable technique to determine global DNA 
methylation levels [65]. 
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 Mass spectrometry (MS) coupled with liquid-chromatography-electrospray ionisation 
spectrometry (ESI-LC-MS) is becoming used increasingly for the detection of DNA adducts 
providing unequivocal identification of the nature of an adduct [55; 66; 67]. The sensitivities 
achieved are normally lower than with 32P-postlabelling but, with the detection of 1 adduct per 108 
to 109 nucleotides using 50–100 µg of DNA, they are sufficient to give useful data on human 
environmental or dietary exposures [67]. Accurate quantitation of DNA adduct levels is achieved by 
the use of a stable isotope internal standard (e.g. labelled either with 15N or 13C). Although mostly 
applied to the detection of specific well-characterised lesions, more recent techniques allow for the 
simultaneous detection of multiple adducts, and this ‘adductome’ approach has potential for the 
detection and characterisation of DNA adducts in human tissues [68]. Accelerator mass 
spectrometry (AMS), which measures isotope ratios, represents the most sensitive analytical 
method so far for detecting DNA adducts, with limits of adduct detection as low as 1 adduct in 1011 
nucleotides [66; 69]. The main limitation of the technique is that it depends on the presence of an 
isotope such as 14C or 3H in the compound of interest. However, because of the high sensitivity of 
AMS, it has been possible to obtain ethical approval to give minute amounts of a radioactive 
carcinogen, for example, 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) or tamoxifen, 
to human individuals prior to surgery and to detect DNA adducts in the excised tissue [70; 71].  
 Other physicochemical methods for the detection of DNA adducts are based on the fact that 
some adducts are highly fluorescent, enabling their detection by fluorescence spectroscopy [55; 72]. 
Combining the fluorescent characteristics (specific excitation and emission wavelengths) with 
HPLC separation techniques make it even possible to detect stereoisomers. Adducts with 
fluorescent properties include those formed by PAHs and aflatoxins, cyclic (etheno) adducts, and 
some methylated adducts [72]. Other adducts, notably 8-oxo-dGuo, are readily detected by HPLC 
coupled with electrochemical detection (ECD) [73]. All these methods can provide a sensitivity of 
detection of around 1 adduct per 108 nucleotides, while requiring relative large quantities (100–
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1000 µg) of sample DNA. Overall, the major limitations of these methods are the required spectral 
(e.g. intrinsic fluorescence) and physicochemical properties of the adducts. 
 Immunoassays have also been used for the detection of DNA adducts in human and 
experimental samples [74; 75]. Antibodies have been raised against a variety of carcinogen-
modified DNAs, including those containing adducts of PAHs, aromatic amines, methylating agents, 
tamoxifen, UV radiation, and oxidative damage. Immunoassays are highly sensitive, but have 
generally been less sensitive than 32P-postlabelling and usually require more DNA for analysis, 
although some recent developments have both increased sensitivity and reduced the amount of 
DNA required, improving the sensitivity to a level closer to that of 32P-postlabelling [76]. When 
combined with histochemistry, cell-specific localisation of adducts in paraffin-embedded tissue is 
possible [77; 78]. However, antibodies can show cross-reactivity with adducts formed by the same 
class of compounds, which can obscure both the nature of the adducts and the levels at which they 
are present. 
 
Biological significance of DNA adducts 
While it is evident that DNA damage and binding by carcinogens occurs in the early, 
initiating stages of carcinogenesis, it has become increasingly clear that damage to DNA is also a 
feature of later stages of the multistage process, now that it is known that mutations in some genes 
are associated with later stages of progression of some types of tumour. It is also evident that the 
formation of DNA adducts is by no means a sufficient event for carcinogenesis, , as DNA adducts 
are frequently detectable in both target and non-target tissues. Nevertheless, inhibition of DNA 
adduct formation will decrease the incidence of tumours formed subsequently, and increasing the 
adduct levels generally leads to a higher tumour yield. Other evidence that strongly links DNA 
adduct formation to tumour initiation is the demonstration that XPA knockout mice, which are 
deficient in nucleotide excision repair, are highly sensitive to tumour induction by carcinogens that 
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form stable adducts that would be removed from DNA in normal mice by this repair mechanism 
[79]. 
 That chemical modification of DNA can result in the same alterations as observed in 
mutated genes in tumours was observed with the H-ras-1 proto-oncogene transfected into NIH3T3 
cells [80]. Prior modification (by reaction with benzo[a]pyrene diol-epoxide, BPDE, the reactive 
metabolite of benzo[a]pyrene; see Figure 1) of the plasmid containing the gene resulted in 
mutations occurring in the DNA after transfection and replication of the host cells, manifested as 
the appearance of transformed foci. Mutations that activate proto-oncogenes such as ras genes 
occur in a few codons in the gene, so correlations between the sites of mutations in such 
experiments may not be very informative. In contrast, for tumour suppressor genes there may be 
many possible sites of DNA damage and mutation that can lead to altered function of the gene 
product that contributes to malignant transformation. Such a gene is TP53, which has been found to 
be mutated in ~50% of human tumours. Correlations can be usefully sought between the mutation 
spectra observed in different human tumours in order to provide clues to the nature of the initiating 
agent(s) [81]. This approach has led to evidence for the involvement of the mycotoxin aflatoxin B1 
in the initiation of liver cancer in regions of high incidence in China, where a G→T transversion in 
codon 249 of TP53 is a common mutation in the disease [82]. In lung cancer, codons 157, 248 and 
273 of the gene are frequently mutated; G→T transversions are much more common in cases of 
lung cancer among smokers than among non-smokers, and these types of mutation are characteristic 
of bulky carcinogens, such as the PAHs, which are present in tobacco smoke. When the sites of 
DNA adduct formation by BPDE in the TP53 gene in HeLa cells and bronchial epithelial cells were 
determined, it was found that codons 157, 248 and 273 were preferentially modified, correlating 
with the frequently mutated sites in lung tumours of smokers [83]. 
 UV causes DNA damage chiefly by dimerisation of adjacent pyrimidines in the same DNA 
strand. The biological importance of these lesions is illustrated by the fact that sufferers of 
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Xeroderma Pigmentosum (XP), who have a deficiency in nucleotide excision repair mechanisms 
that remove pyrimidine dimers and other bulky adducts from DNA (also deficient in XPA knock-
out mice mentioned above), are prone to sunlight-induced skin cancer. Moreover, the type of TP53 
mutation found commonly in such tumours, but rarely in tumours of internal organs, is a tandem 
mutation occurring at pyrimidine pairs (CC→TT transitions), highly suggestive that it arose from 
UV-induced pyrimidine dimers [84]. 
 Thus, there are examples of genetic changes in tumours that closely match the genetic 
changes that can be induced experimentally in cellular DNA by specific genotoxic agents. These 
tumour-specific mutations in TP53 and the demonstration that chemically-modified DNA 
transforms cells show that the mutations observed in human tumours could have arisen from the 
formation of carcinogen-DNA adducts in vivo. Clonal expansion of the mutated cells and the 
acquisition of further genetic alterations eventually leads to malignancy [3]. 
 
Adducts as biomarkers of occupational and environmental exposure to carcinogens 
 Sensitive DNA adduct detection methods, not requiring the use of radiolabelled carcinogens, 
make it possible to monitor DNA isolated from human tissues for evidence of prior exposure to 
carcinogens. Many different tissues have provided DNA for such studies [85], including blood, 
sputum, buccal mucosa, cervical mucosa, sperm, bladder (exfoliated urothelial cells in urine), 
placenta and hair roots. DNA from these accessible sources of human cells have been used in many 
studies, but by far the most commonly used tissue source has been blood cells (either lymphocytes 
or the whole fraction of nucleated white blood cells). While these are not target cells for 
malignancy, they are useful surrogates and are known to display evidence of genotoxic exposure 
using other, less sensitive, endpoints, such as micronucleus formation, chromosomal aberrations 
and mutation in reporter genes such as HPRT. 
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Heavy industries where an increased risk of lung and other cancers has been observed 
include iron and steel production, aluminium production, coke ovens and graphite electrode 
manufacture. The principal genotoxic exposure in these industries is to PAHs. Many studies have 
investigated DNA adduct formation in workers in these industries, using white blood cells as the 
monitored tissue. In general, the results of such studies have been the demonstration of statistically 
significant increases in the level of DNA adducts in the exposed workers, compared with controls 
[86]. Other industrial workforces studied, with similar results, include roofers, chimney sweeps, 
incinerator workers, petrol refinery workers, traffic police and bus maintenance workers [86]. 
 DNA adduct detection can also be used to investigate environmental exposure to genotoxic 
carcinogens [86]. For example, chronic environmental exposure to industrial sources of carcinogens 
has occurred in Upper Silesia and the Krakow region of Poland, and in Northern Bohemia in the 
Czech Republic. Studies on these populations have revealed significantly elevated levels of DNA 
adducts in blood cells compared with control populations from rural areas of the same countries. In 
Xuan Wei province of China, the practice of using smoky coal for cooking and heating in 
unventilated houses leads to a high level of smoke indoors and high incidences of lung cancer, 
particularly in the women (very few of whom smoke tobacco). Placental, blood and lung (from 
bronchoalveolar lavage) cells have all been used as sources of DNA to compare exposed female 
residents of Xuan Wei with a control group from Beijing, and in each case evidence for elevated 
levels of adducts was obtained [87]. In Henan province of China, there is an exceptionally high 
prevalence of oesophageal cancer and, among several suspected environmental factors, the high 
content of PAHs in the diet has recently become of interest; evidence that this may play a role in the 
aetiology of the disease is supported by the observation of high levels of PAH-DNA adducts, 
detected by immunohistochemistry, in archived surgical specimens of oesophagi from the region 
[88]. 
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 A recent example of the identification of a human carcinogen is aristolochic acid (AA), a 
constituent of plants of the genus Aristolochia. AA is genotoxic, being positive in many short-term 
tests, and forms covalent DNA adducts in tissues of rodents, and in human cells in culture [89]. An 
outbreak of renal failure, followed by urothelial cancer in some of the patients, occurred among 
individuals in Belgium who took a slimming regimen containing Chinese herbs, one of which 
turned out to be an Aristolochia species. 32P-Postlabelling analysis of DNA from the tissues of these 
patients revealed the presence of AA-DNA adducts, implicating the compound as the genotoxic 
agent involved in the carcinogenic process leading to urothelial tumours [90]. The renal disease, 
now known as Aristolochic acid nephropathy (AAN), is pathologically similar to Balkan endemic 
nephropathy (BEN), in which AA is also implicated [91]. The source is thought to Aristolochia 
clematitis, which grows wild in the Balkans and whose seeds may contaminate wheat flour in the 
region. The detection of AA-DNA adducts in renal tissues from BEN sufferers provides strong 
evidence for the involvement of AA in the aetiology of the disease [92]. Furthermore, analysis of 
TP53 mutations in BEN tumours, and in one AAN tumour, shows a preponderance of AT-TA 
transversion mutations, which is the predominant mutation that AA causes in experimental studies 
[92] [93]. 
The relationship between DNA adduct formation and tobacco smoking has been widely 
studied and used to validate the biomarker (see below). Tobacco smoke contains at least 50 
compounds that are known to be carcinogenic, including representatives of several distinct classes 
of compounds (PAHs, aromatic amines, N-nitrosamines, aza-arenes, aldehydes, other organic 
compounds and inorganic compounds). Most of these compounds are genotoxic carcinogens that 
form DNA adducts. In many studies that have compared DNA from smokers, ex-smokers and non-
smokers, higher levels of adducts have been found in many target tissues of smokers: lung, 
bronchus, larynx, bladder, cervix and oral mucosa [94]. In some of these studies a linear correlation 
between estimated tobacco smoke exposure and adduct levels has been observed. In tissues of the 
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respiratory tract adduct levels in ex-smokers tend to be intermediate between smokers and non-
smokers, indicating that adducts are removed through DNA repair and/or cell turnover. The half-life 
of adduct persistence appears to be between one and two years.  
For some of these studies specific adducts have been detected, but in others a more general 
measure of DNA damage has been made, namely aromatic/hydrophobic adducts detected by 32P-
postlabelling, or PAH-DNA adducts detected by immunoassay. Recent studies have found that 
when adduct levels are adjusted to take account of the level of tobacco smoke exposure, lung DNA 
from women smokers is more highly adducted that that of male smokers. This finding is interesting 
in view of epidemiological evidence suggesting that women are at a 1.5-2-fold greater risk of lung 
cancer from smoking. It would appear that the adduct analysis provides biochemical, mechanistic 
evidence to support the morbidity data [95]. 
Some, but not all, studies have shown elevated levels of lung adducts in cancer cases 
compared with controls. The relationship between adduct levels in target tissues (e.g. lung) and 
other tissues (e.g. blood) has been investigated to see whether the latter can serve as a valid 
accessible surrogate source of DNA for the former. Results for smoking-related adducts have been 
inconsistent [54; 96], perhaps because other sources of exposure to some classes of carcinogens, 
such as PAHs, which are also ingested as dietary contaminants, may contribute to the overall level 
of adducts in the blood but not to the same extent in the lung. 
 
DNA adducts in prospective studies 
When measuring adducts in smokers at the time of cancer diagnosis (e.g. in case-control 
studies), investigators are not looking at the biochemical events causal in the initiation of those 
tumours, as these would have occurred decades earlier. However, because smoking is addictive and 
habitual for the vast majority of tobacco users, DNA adducts in tumour-adjacent tissue at the time 
of tumour manifestation can still serve as a useful biomarker that gives an indication of an 
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individual's probable steady-state level of DNA damage maintained over a long period of time. In 
order to determine whether DNA adducts have predictive value in cancer risk, it is necessary to 
conduct prospective studies in which DNA samples are collected and stored from a large cohort of 
individuals who are then followed up to determine who does and who does not develop cancer in 
the future. It is then possible to perform a nested case-control study within the cohort to determine 
whether DNA adduct analysis of the stored samples reveals whether differences between the two 
groups were evident prior to the onset of disease. 
The first example of this approach was a study conducted in Shanghai, China, where a high 
incidence of liver cancer is associated with dietary exposure to aflatoxin B1, 18, 244 men provided a 
single urine sample and provided detailed dietary questionnaire data, in addition to which food 
analyses were carried out [97]. When 55 cases of liver cancer subsequently arose in the cohort, 
these were matched to 267 disease-free controls and their urine samples analysed by HPLC-
fluorescence to detect the presence of aflatoxin derivatives. A significant association was found 
between the presence of aflatoxin metabolites, including the aflatoxin-N7-guanine adduct, and liver 
cancer. Interestingly, when data obtained from questionnaires and food analyses were considered 
without the biomarker data, no association between exposure and liver cancer was evident. Thus in 
this case the power of biomarkers of exposure showed a clear advantage over more traditional 
means of exposure assessment to show a causal association. 
The ability of DNA adducts to predict lung cancer risk was investigated in tobacco smokers 
[98]. From a follow-up of a cohort of 15, 700 males who had provided blood samples at the outset 
of the study, 93 cases of lung cancer were identified and matched to 173 controls. Analysis of white 
blood cell DNA by 32P-postlabelling revealed that smokers who got lung cancer had 2-fold higher 
levels of bulky/hydrophobic DNA adducts than smokers who did not. The smokers who had 
elevated levels of adducts were approximately three times more likely to be diagnosed with lung 
cancer 1-13 years later than the smokers with lower adduct concentrations. 
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The predictive power of DNA adducts to distinguish groups of individuals who developed 
cancer from those who did not was also investigated in two recent studies that measured bulky 
DNA adducts in leukocytes by 32P-postlabelling analysis. In the first, 115 cases of lung cancer were 
matched with twice the number of controls from European cohorts totalling more than 500, 000 
people [99]. Detectable DNA adducts were significantly more common in non-smokers and long-
term ex-smokers who developed lung cancer than in those who did not. The second study 
investigated 245 individuals with lung cancer and 255 without, from a population-based cohort of 
53, 689 men and women [100]. The median level of DNA adducts was significantly higher for 
smokers who developed lung cancer than for those that did not. Although adduct levels were 
statistically significantly higher in the cases in both these studies, the numerical differences from 
the controls was somewhat small. Thus the ability to predict cancer risk from DNA adduct 
measurements on an individual basis will be very limited, despite the collective differences between 
the cases and the controls. Nevertheless, DNA adduct analysis should have applications in 
investigating the efficacy of chemoprevention strategies by, for example, documenting a reduction 
in adduct levels concomitant with a reduction in cancer risk in interventions in an occupationally- or 
environmentally-exposed population. 
 
Summary 
DNA adduct formation, or the causation of DNA damage by less direct means, is an 
important property of genotoxic agents. The strategies that have been developed for determining the 
carcinogenic potential of chemicals, using short-term tests, are based on detecting evidence of either 
DNA damage or its biological consequences. Although it is well recognised that the carcinogenic 
activity of some chemicals is the result of non-genotoxic mechanisms, the majority of known 
human carcinogens are genotoxic. Early studies on DNA adducts required use of radioactively 
labelled compounds, but alternative methods with a high degree of sensitivity and selectivity have 
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since been developed, enabling their wider application, including the monitoring of human exposure 
to environmental carcinogens and in providing clues to the aetiology of some cancers. Experimental 
interventions that reduce DNA adduct formation also reduce carcinogenicity, while enhancing DNA 
adduct formation has the opposite effect. In prospective studies, elevated DNA adducts have been 
found in individuals who subsequently developed cancer relative to those who did not. Continuing 
research into the detection and characterisation of DNA adducts in human tissues will shed further 
light on the causative agents of human cancers. 
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Table 1. Performance terms for short-term tests for genotoxicity 
 
Test outcome Carcinogen 
 
 Yes 
 
No Total 
 
Positive 
 
a 
 
b 
 
a + b 
 
Negative 
 
c 
 
d 
 
c + d 
 
Total 
 
 
a + c 
 
c + d 
 
N = a + b + c + d 
 
Term 
 
Definition 
 
Description 
 
Sensitivity 
 
a/(a + c) 
 
number of carcinogens found positive 
  number of carcinogens tested 
 
Specificity 
 
d/(b + d) 
 
number of non-carcinogens found negative 
  number of non-carcinogens tested 
 
Positive predictivity 
 
a/(a + b) 
 
number of carcinogens found positive 
  number of positive results obtained 
 
Negative predictivity 
 
d/(c + d) 
 
number of non-carcinogens found negative 
  number of negative results obtained 
 
Accuracy 
 
(a + d)/N 
 
number of correct test results 
  number of chemicals tested 
 
Adapted from Anon [101] and Shelby and Purchase [102] 
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Table 2: Some representative carcinogens, their environmental sources, their active metabolites, 
sites of modification of DNA, and major type of induced mutation 
 
 
OH
HO
O
Benzo[a]pyrene (BaP) BaP 7,8-dihydrodiol 9,10-oxide (BPDE)
Tobacco smoking
Combustion processes 
O
O
O
CH3
O O
Aflatoxin B1 (AFB1)
O
O
O
CH3
O O
O
AFB1 8,9-epoxide
Mycotoxin
N N
N
CH3
NH2
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) 
Food processing 
N N
N
CH3
H
N OAc
N-Acetoxy-PhIP
O
N(CH3)2
Tamoxifen
Anticancer drug 
O
N(CH3)2
OSO3H
α-Hydroxytamoxifen sulphate
O
NO2
3-Nitrobenzanthrone
Diesel exhaust
Urban air pollution 
O
N OH
H
N-Hydroxy-3-aminobenzanthrone
Aristolochic acid I (AAI) 
Aristolochia species 
N-Hydroxyaristolactam I 
N2-Guanine
N6-Adenine 
N7-Guanine
C8-Guanine 
N2-Guanine
N6-Adenine
N2-Guanine
C8-Guanine
N6-Adenine
N2-Guanine
N6-Adenine
O
O
OCH3
COOH
NO2
GC → TA
GC → TA
GC → TA
GC → TA
GC → TA
AT → AT
Carcinogen Environmental
source
Sites of modification
of DNA
Major active metabolite Major type
of mutation
O
O
N
OCH3
OH
O
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Table 3. DNA adduct detection methods applicable to human biomonitoring and their limits of 
detection 
 
Method Variations Amount of DNA 
required 
 
Approximate detection 
limits 
32P-postlabelling Nuclease P1 digestion, 
butanol extraction, HPLC 
 
1-10 µg 1 adduct per 109-1010 
nucleotides 
Immunoassay ELISA, DELFIA, CIA, 
IHC 
 
20 µg 1.5 adducts per 109 
nucleotides 
Fluorescence HPLC fluorescence, SFS 
 
100-1000 µg 1 adduct per 109 
nucleotides 
 
Mass Spectrometry  Up to 100 µg 1 adduct per 108 
nucleotides 
 
AMSa  Up to 100 µg 1 adduct per 1011-1012 
nucleotides 
 
 
a
 Accelerator mass spectrometry. Requires use of radiolabelled compounds 
Reproduced from [103] 
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Figure 1: Major pathway of metabolic activation and DNA adduct formation of benzo[a]pyrene (see 
text for details). CYP1A1, cytochrome P450 1A1; EH, epoxide hydrolase. 
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